» Articles » PMID: 19372990

The Mucosal Barrier and Immune Activation in HIV Pathogenesis

Overview
Date 2009 Apr 18
PMID 19372990
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Significant gastrointestinal pathology occurs in progressive HIV and simian immunodeficiency virus (SIV) infections. This review will examine the relationship between the detrimental events to the gastrointestinal tract during the acute phase of infection and disease progression through the chronic phase and, ultimately, AIDS.

Recent Findings: Gastrointestinal tract CD4 T cells are dramatically depleted in acutely HIV-infected humans and SIV-infected rhesus macaques, sooty mangabeys, and African green monkeys. In addition HIV infection of humans and SIV-infection of rhesus macaques are characterized by enteropathy and increased intestinal permeability. While SIV-infected rhesus macaques and HIV-infected humans manifest chronic and systemic immune activation and microbial translocation, and progress to chronic infection and AIDS, however, SIV-infected sooty mangabeys and African green monkeys do not.

Summary: Recent studies have increased our understanding of the mechanisms relating structural and immunological damage to the gastrointestinal tract during the acute phase of HIV/SIV infection to immune activation and disease progression in the chronic phase.

Citing Articles

Role of the gut-brain axis in HIV and drug abuse-mediated neuroinflammation.

Ray S, Sil S, Kannan M, Periyasamy P, Buch S Adv Drug Alcohol Res. 2024; 3:11092.

PMID: 38389809 PMC: 10880759. DOI: 10.3389/adar.2023.11092.


Cannabis Use and Biomarkers of Inflammation, Immune Activation, and Microbial Translocation in Persons with HIV.

Okafor C, Somasunderam A, Lake J, Gelfond J, Javanbakht M, Gorbach P Cannabis Cannabinoid Res. 2024; 9(6):e1579-e1587.

PMID: 38335314 PMC: 11685291. DOI: 10.1089/can.2023.0109.


The microbiota as a modulator of mucosal inflammation and HIV/HPV pathogenesis: From association to causation.

Moreno E, Ron R, Serrano-Villar S Front Immunol. 2023; 14:1072655.

PMID: 36756132 PMC: 9900135. DOI: 10.3389/fimmu.2023.1072655.


Interleukin-27 Promotes Divergent Effects on HIV-1 Infection in Peripheral Blood Mononuclear Cells through BST-2/Tetherin.

Temerozo J, Ferreira P, Linhares-Lacerda L, Vieira R, Cister-Alves B, Gobbo L J Virol. 2023; 97(1):e0175222.

PMID: 36602368 PMC: 9888194. DOI: 10.1128/jvi.01752-22.


Natural Killer Cells Regulate Acute SIV Replication, Dissemination, and Inflammation, but Do Not Impact Independent Transmission Events.

Woolley G, Mosher M, Kroll K, Jones R, Hueber B, Sugawara S J Virol. 2022; 97(1):e0151922.

PMID: 36511699 PMC: 9888193. DOI: 10.1128/jvi.01519-22.


References
1.
Clayton F, Kotler D, Kuwada S, Morgan T, Stepan C, Kuang J . Gp120-induced Bob/GPR15 activation: a possible cause of human immunodeficiency virus enteropathy. Am J Pathol. 2001; 159(5):1933-9. PMC: 1867054. DOI: 10.1016/S0002-9440(10)63040-4. View

2.
Beignon A, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh D . Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest. 2005; 115(11):3265-75. PMC: 1253628. DOI: 10.1172/JCI26032. View

3.
Hazenberg M, Stuart J, Otto S, Borleffs J, Boucher C, de Boer R . T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 1999; 95(1):249-55. View

4.
Giorgi J, Hultin L, McKeating J, Johnson T, Owens B, Jacobson L . Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999; 179(4):859-70. DOI: 10.1086/314660. View

5.
Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A . Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003; 77(21):11708-17. PMC: 229357. DOI: 10.1128/jvi.77.21.11708-11717.2003. View